Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD

Secondary point mutations in the Fms-like tyrosine kinase 3 (FLT3) tyrosine kinase domain (KD) are common causes of acquired clinical resistance to the FLT3 inhibitors AC220 (quizartinib) and sorafenib. Ponatinib (AP24534) is a multikinase inhibitor with in vitro and clinical activity in tyrosine ki...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Smith, Catherine C., Lasater, Elisabeth A., Zhu, Xiaotian, Lin, Kimberly C., Stewart, Whitney K., Damon, Lauren E., Salerno, Sara, Shah, Neil P.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2013
Assuntos:
Myeloid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3630831/
https://ncbi.nlm.nih.gov/pubmed/23430109
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-07-442871
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados